Cover Image
市場調查報告書

全球靜脈注射Ibuprofen市場機會與預測

World Intravenous (IV) Ibuprofen Market - Opportunities and Forecasts, 2015 - 2022

出版商 Allied Market Research 商品編碼 358471
出版日期 內容資訊 英文 65 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球靜脈注射Ibuprofen市場機會與預測 World Intravenous (IV) Ibuprofen Market - Opportunities and Forecasts, 2015 - 2022
出版日期: 2016年04月16日 內容資訊: 英文 65 Pages
簡介

全球靜脈注射Ibuprofen市場預計將從2015年的360萬美元,到2022年擴大到1,420萬美元。市場在2015年∼2022年這段期間預測將以年複合成長率 (CAGR) 20%的速度成長。

本報告提供全球靜脈注射Ibuprofen市場相關調查分析,提供您市場概要,各市場區隔的市場分析,各地區分析,競爭情形等系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特的五力分析
  • 政府的法規
  • 研究·分析
  • 市場動態

第4章 全球止痛藥市場:各年齡層

  • 兒童
  • 成人

第5章 全球止痛藥市場:各適應症

  • 發熱

第6章 全球止痛藥市場:各國

  • 市場規模與預測
  • 美國
  • 加拿大
  • 澳洲
  • 韓國

第7章 企業簡介

  • 企業概要,實際成果,策略與發展,SWOT分析等
    • Cumberland Pharmaceuticals Inc.
    • Alveda Pharmaceuticals, Inc.
    • CSL Limited
    • Sandor Medicaids Pvt Ltd.
    • PT. Soho Industri Pharmasi
    • Germin MED
    • Grifols S.A.
    • Harbin Gloria Pharmaceuticals Co., Ltd.
    • Al Nabeel International Ltd.
    • Laboratorios Valmorca, C.A.

圖表

目錄

Title: World Intravenous (IV) Ibuprofen Market by Indication (Pain/Inflammatory, Fever) and Age Group (Pediatrics, Adults) - Global Opportunity Analysis and Industry Forecast, 2015 - 2022.

Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.

The market for IV ibuprofen for pain management is in its nascent stage. The world IV ibuprofen market was valued at $3.6 million in 2015, and is projected to reach $14.2 million by 2022, registering a CAGR of 20% during the forecast period. Advantages associated with IV ibuprofen such as rapid result and targeted drug delivery have resulted in the growth of this market. In 2015, FDA approved IV ibuprofen for pediatric use, due to which the market is expected to register a significant growth during the forecast period. Other factors that affect the market growth significantly include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma, and shifting trend towards the use of non-opioids drugs. Factors that would hamper the market growth include side effects associated with IV ibuprofen and lengthy approval process.

The world IV Ibuprofen market is segmented on the basis of indication, age group, and country. By indication, further sub-segments considered in this report include pain/inflammation and fever. The age groups considered are pediatrics and adults. The market is segmented into four countries namely Australia, Canada, South Korea, and the U.S.

Currently, Cumberland Pharmaceuticals Inc., is the only IV ibuprofen manufacturer in the market. The company has collaborated with the local/regional drug manufacturers to target new countries by getting product approvals. The key companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond: what to expect by 2027
    • 2.2.1. Moderate scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porters five forces analysis
  • 3.4. Government regulations
  • 3.5. Research & Analysis
    • 3.5.1. Clinical trials
  • 3.6. Market dynamics
    • 3.6.1. Drivers
    • 3.6.2. Restraints
    • 3.6.3. Opportunities

CHAPTER 4: WORLD ANALGESICS MARKET, BY AGE GROUP, 2015-2022

  • 4.1. Pediatrics
    • 4.1.1. Market size and forecast
  • 4.2. Adults
    • 4.2.1. Market size and forecast

CHAPTER 5: WORLD ANALGESICS MARKET, BY INDICATION, 2015-2022

  • 5.1. Pain
    • 5.1.1. Market size and forecast
  • 5.2. Fever
    • 5.2.1. Market size and forecast

CHAPTER 6: WORLD ANALGESICS MARKET, BY COUNTRY, 2015-2022

  • 6.1. Market size and forecast for IV ibuprofen
  • 6.2. United States
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast for actual IV ibuprofen
  • 6.3. Canada
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast for actual IV ibuprofen
  • 6.4. Australia
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast for actual IV ibuprofen
  • 6.5. South Korea
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast for actual IV ibuprofen

CHAPTER 7: COMPANY PROFILES

  • 7.1. Cumberland Pharmaceuticals Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Business performance
    • 7.1.5. Key strategic moves and developments
    • 7.1.6. SWOT analysis
  • 7.2. Alveda Pharmaceuticals, Inc. (Acquired by Teligent, Inc.)
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Business performance
    • 7.2.5. Key strategic moves and developments
    • 7.2.6. SWOT analysis
  • 7.3. CSL Limited
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Business performance
    • 7.3.5. Key strategic moves and developments
    • 7.3.6. SWOT analysis
  • 7.4. Sandor Medicaids Pvt Ltd.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Business performance
    • 7.4.5. Key strategic moves and developments
    • 7.4.6. SWOT analysis
  • 7.5. PT. Soho Industri Pharmasi
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Business performance
    • 7.5.5. Key strategic moves and developments
    • 7.5.6. SWOT analysis
  • 7.6. Germin MED
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Business performance
    • 7.6.5. Key strategic moves and developments
    • 7.6.6. SWOT analysis
  • 7.7. Grifols S.A.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Business performance
    • 7.7.5. Key strategic moves and developments
    • 7.7.6. SWOT analysis
  • 7.8. Harbin Gloria Pharmaceuticals Co., Ltd.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Business performance
    • 7.8.5. Key strategic moves and developments
    • 7.8.6. SWOT analysis
  • 7.9. Al Nabeel International Ltd.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Business performance
    • 7.9.5. Key strategic moves and developments
    • 7.9.6. SWOT analysis
  • 7.10. Laboratorios Valmorca, C.A.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Business performance
    • 7.10.5. Key strategic moves and developments

List of Tables

  • TABLE 1: WORLD IV IBUPROFEN MARKET, MODERATE SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
  • TABLE 2: WORLD IV IBUPROFEN MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
  • TABLE 3: WORLD IV IBUPROFEN MARKET, DIMINISHING GROWTH SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
  • TABLE 4: CLINICAL TRIALS - ANALGESICS
  • TABLE 5: GLOBAL INCIDENCES OF DISEASES
  • TABLE 6: WORLD IV IBUPROFEN MARKET BY AGE GROUP, 2015-2022 ($MILLION)
  • TABLE 7: WORLD PEDIATRIC IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 8: WORLD ADULT IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 9: WORLD PAIN IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 10: WORLD FEVER IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 11: WORLD IV IBUPROFEN MARKET, BY COUNTRY, 2015-2022 ($MILLION)
  • TABLE 12: UNITED STATES: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
  • TABLE 13: CANADA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
  • TABLE 14: AUSTRALIA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
  • TABLE 15: SOUTH KOREA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
  • TABLE 16: COMPANY SNAPSHOT OF CUMBERLAND PHARMACEUTICALS
  • TABLE 17: CUMBERLAND PHARMACEUTICALS OPERATING SEGMENTS
  • TABLE 18: COMPANY SNAPSHOT OF ALVEDA PHARMACEUTICALS, INC.
  • TABLE 19: ALVEDA PHARMACEUTICALS, INC. OPERATING SEGMENTS
  • TABLE 20: COMPANY SNAPSHOT OF CSL LIMITED
  • TABLE 21: CSL LIMITED OPERATING SEGMENTS
  • TABLE 22: COMPANY SNAPSHOT OF SANDOR MEDICAIDS PVT LTD.
  • TABLE 23: SANDOR MEDICAIDS PVT LTD. OPERATING SEGMENTS
  • TABLE 24: COMPANY SNAPSHOT OF PT. SOHO INDUSTRI PHARMASI
  • TABLE 25: PT. SOHO INDUSTRI PHARMASI OPERATING SEGMENTS
  • TABLE 26: COMPANY SNAPSHOT OF GERMINMED
  • TABLE 27: GERMINMED OPERATING SEGMENTS
  • TABLE 28: COMPANY SNAPSHOT OF GRIFOLS S.A.
  • TABLE 29: GRIFOLS S.A. OPERATING SEGMENTS
  • TABLE 30: COMPANY SNAPSHOT OF HARBIN GLORIA PHARMACEUTICALS CO., LTD.
  • TABLE 31: COMPANY SNAPSHOT OF AL NABEEL INTERNATIONAL LTD.
  • TABLE 32: AL NABEEL INTERNATIONAL LTD. OPERATING SEGMENTS
  • TABLE 33: COMPANY SNAPSHOT OF LABORATORIOS VALMORCA
  • TABLE 34: LABORATORIOS VALMORCA OPERATING SEGMENTS

List of Figures

  • FIG. 1: TOP IMPACTING FACTORS, MODERATE SCENARIO (2022-2027)
  • FIG. 2: TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)
  • FIG. 3: TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)
  • FIG. 4: TOP INVESTMENT POCKETS OF IV IBUPROFEN MARKET BY COUNTRY, 2015-2022
  • FIG. 5: TOP WINNING STRATEGIES
  • FIG. 6: IV IBUPROFEN MARKET SHARE ANALYSIS, 2014
  • FIG. 7: TOP FACTORS IMPACTING WORLD IV IBUPROFEN MARKET, 2015-2022
  • FIG. 8: REVENUE GENERATED BY CUMBERLAND PHARMACEUTICALS (2012-2014)
  • FIG. 9: CUMBERLAND PHARMACEUTICALS, %REVENUE, BY PRODUCT, (2014)
  • FIG. 10: SWOT ANALYSIS OF CUMBERLAND PHARMACEUTICALS
  • FIG. 11: REVENUE GENERATED BY CSL LIMITED (2013-2015)
  • FIG. 12: CSL LIMITED, %REVENUE, BY BUSINESS SEGMENTS, (2014)
  • FIG. 13: CSL LIMITED, % REVENUE, BY GEOGRAPHY (2014)
  • FIG. 14: SWOT ANALYSIS OF CSL LIMITED
  • FIG. 15: REVENUE GENERATED BY GRIFOLS S.A. (2012-2014)
  • FIG. 16: GRIFOLS S.A., %REVENUE, BY BUSINESS SEGMENTS, (2014)
  • FIG. 17: GRIFOLS S.A., % REVENUE, BY GEOGRAPHY (2014)
  • FIG. 18: SWOT ANALYSIS OF GRIFOLS S.A.
Back to Top